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A bidirectional communication between the immune and endocrine systems exists and 
facilitates optimum responses in the host during infections. This is in part achieved through 
changes in secretion patterns of hypothalamic hormones induced by inflammatory cyto-
kines. The aim of this study was to elucidate the immune–endocrine alterations during 
tuberculosis (TB) treatment in patients with cured and failed TB treatment outcomes. 
Blood samples were collected from 27 cured and 10 failed patients and hormone as well 
as cytokine concentrations quantified at baseline, week 4, and month 6 of TB treatment. 
Hormone profiles of the two treatment outcome groups were different from each other 
prior to as well as during TB treatment. Treatment response effects were observed for 
cortisol, estradiol, T3, T4 ghrelin, leptin, amylin, adiponectin, and dehydroepiandroste-
rone (DHEA). Trends suggest that T4, amylin, and DHEA concentrations were different 
between treatment outcomes, although these did not reach statistical significance. 
Relationships between endocrine and inflammatory markers and the biological pathways 
involved differed between cured and failed treatment patients. These results highlight 
the complex interaction between the endocrine and immune system during active TB 
disease and throughout treatment and suggest that endocrine markers in conjunction 
with inflammatory markers may be useful in predicting unfavorable treatment outcomes.
Keywords: tuberculosis, biomarkers, immune, endocrine, cytokines, metabolic hormones, steroid hormones
inTrODUcTiOn
Tuberculosis (TB), caused by Mycobacterium tuberculosis (M.tb), is a major global health threat, 
particularly in developing countries and continues to claim approximately two million lives every 
year (1). According to the World Health Organization, South Africa is estimated to have the high-
est TB incidence at 860 per 100,000 population (1). The estimated detection rate for TB increased 
Abbreviations: BMI, body mass index; CRP, C-reactive protein; CXR, chest X-ray; DHEA, dehydroepiandrosterone; FXR, 
farnesoid X receptor; IL, interleukin; LXR, liver X receptor; MMP, matrix metalloproteinase; M.tb, Mycobacterium tuberculosis; 
PCA, principal component analysis; RXR, retinoid-X-receptor; TB, tuberculosis; TNF, tumor necrosis factor; TREM1, trigger-
ing receptor expressed on myeloid cells 1.
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from 58 to 69% between 2000 and 2013 (1). However, approaches 
to control TB have failed to contain the epidemic. In addition, 
rapidly increasing rates of recurrent TB episodes and increasing 
rates of multi-drug resistant (MDR) TB present a startling public 
health emergency (2).
In response to an infection, cytokines like interleukin (IL)-1, 
IL-6, and tumor necrosis factor (TNF)α, produced by immune 
cells, can activate the hypothalamus–pituitary–adrenal (HPA) 
axis, which results in the secretion of cortisol (3). These 
cytokines furthermore affect the functioning of the hypo-
thalamus–pituitary–thyroid (HPT) axis (4) as well as the hypo-
thalamus–pituitary–gonadal (HPG) axis (resulting in decreased 
secretion of androgenic hormones) (5, 6). Cortisol, in turn, 
inhibits the mycobacterial antigen-induced cytokine response of 
peripheral blood mononuclear cells (7, 8). This communication 
pattern exists due to the fact that cytokine-producing cells as well 
as hormone-producing cells share common receptors and ligands 
(9). This bidirectional communication between the immune and 
endocrine system facilitates optimal responses and maintains 
homeostasis in the host.
Immune and endocrine alterations were observed in TB 
patients, characterized by increased cortisol, estradiol, prolactin, 
growth hormone, thyroid hormone, and dopamine concentra-
tions, which were accompanied by increased interferon (IFN)γ, 
TNFα, C-reactive protein (CRP), IL-1α, IL-6, and IL-10 con-
centrations when compared to healthy controls (4, 10–12). TB 
patients furthermore had decreased dehydroepiandrosterone 
(DHEA) and testosterone concentrations, alterations that were 
more evident in individuals diagnosed with advanced TB disease. 
Leptin concentrations were decreased and ghrelin concentra-
tions increased with increasing disease severity (11, 13, 14). 
Epinephrine concentrations were also lower in TB patients (12). 
Differences in hormone concentrations in the context of TB were 
mostly evaluated at baseline with limited reference being made 
to endocrine profile changes during TB treatment. In one such 
study, Bongiovanni et al. showed that cortisol plasma concentra-
tions decreased during TB treatment together with IL-6, CRP, and 
IL-1β (15). Additionally, DHEA plasma concentrations increased 
during TB treatment.
The aim of this study was to elucidate the immune–endocrine 
alterations during TB treatment in a cohort of HIV negative TB 
patients with different treatment outcomes. The study collectively 
investigated the concentrations of 12 hormones, ranging from 
peptide to steroid hormones, during the course of TB treatment 
in cured patients and in patients with treatment failure. These 
included cortisol, DHEA, T3, T4, adiponectin, leptin, ghrelin, 
active amylin, total amylin, growth hormone, estradiol, and 
progesterone. Furthermore, the association of the hormone 
concentrations with 30 immune markers including cytokines, 
chemokines, growth factors, soluble receptors, acute phase pro-
teins, and matrix metalloproteinases (MMPs) was determined. 
This study is unique in that it is the first treatment response 
study that investigates alterations in hormone concentrations in 
patients with two different treatment outcomes, namely cured 
and treatment failure. We show that the hormone profiles change 
during TB treatment and that the concentrations of different 
hormones correlate with the concentrations of cytokines. These 
results emphasize the complex interaction between the endocrine 
and the immune systems during TB treatment and suggest that 
hormone concentrations in conjunction with inflammatory 




Ethical approval was obtained from the Health Research Ethics 
Committee of the University of Stellenbosch and the City of 
Cape Town City Health. The study was conducted according to 
the Helsinki Declaration and International Conference of Harmo-
nization guidelines. Written informed consent was obtained from 
all study participants.
study subjects
Study participants, 27 cured and 10 failed TB patients, were 
enrolled and treated at 5 TB clinics surrounding Tygerberg Hos-
pital in Cape Town, South Africa, between May 1999 and July 
2002, as part of the Action TB study (16). The HIV uninfected 
pulmonary TB patients were all from the South African Colored 
ethnic group and were untreated at the time of enrollment with 
a first episode of TB. All TB patients received directly observed 
treatment, which consisted of an intensive phase (2 months) of 
rifampicin (RIF), isoniazid (INH), pyrazinamide, and etham-
butol (EMB) followed by a continuation phase (4  months) of 
RIF and INH. The 2-month intensive phase was prolonged to 
3  months if smear conversion did not occur at 2  months. The 
percentage of individuals requiring extended intensive phase was 
15 and 45% for the cured and failed group, respectively. Patients 
were between the ages of 20 and 65 years. Patients were matched 
based on their gender and sample storage time. Individuals who 
had two consecutive negative culture results at the end of treat-
ment were regarded as successfully cured whereas those who 
had a positive culture result at month 6 had failed treatment. All 
individuals adhered to treatment (>80% of drugs taken) and were 
infected with drug sensitive M.tb strains. No distinct differences 
in strain types were observed between failed and cured patients. 
Patients were excluded if they previously had TB; MDR TB, were 
HIV positive, presented with diabetes, malignancy, lung cancer, 
chronic bronchitis, or sarcoidosis, were on steroid treatment 
or were pregnant. Chest X-rays (CXRs) were only obtained at 
baseline and were read independently in a blinded fashion by a 
pulmonologist or clinician as previously described (17).
sample collection and Processing
Samples were collected between 09h00 and 12h00 every day. 
Clinical information on age, sex, weight, and height (BMI) was 
recorded. Sputum samples were obtained at baseline and at week 
4 and month 6 of treatment. Sputum smear microscopy was done 
using the Ziehl–Neelsen method and quantitative smear grading 
done according to the International Union Against Tuberculosis 
and Lung Disease guidelines (18). The same sample that was 
used for sputum smear microscopy was used to determine time-
to-positivity in liquid culture using the BACTEC 12B liquid 
Table 1 | Characteristics of study groups.
cured (n = 27) Failed (n = 10) p-Value
BMI (kg/m2), BL 18.1 ± 2.1 18.8 ± 1.9 0.33
BMI (kg/m2), W4 18.5 ± 2.4 19.3 ± 1.5b 0.18
BMI (kg/m2), M6 19.5 ± 2.1a 19.8 ± 1.7a 0.68
Age (years) 35.0 ± 10.42 38.6 ± 11.9 0.44
Sex (F/M) 14/13 5/5
CXR score 57.6 ± 31.3 71.7 ± 34.1 0.31
Differences between groups were determined by a Mann–Whitney U test. Results are 
shown as mean ± SD.
BL, baseline; W4, week 4; M6, month 6; F, female; M, male; BMI, body mass index; 
CXR, chest X-ray.
a and b, significantly different from BL of the same group.
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radiometric method (BD, NJ, USA) as previously described (16). 
At each of the indicated time points, blood was drawn, and the 
serum and plasma aliquoted and stored at −80°C.
Quantification of serum cytokine  
and Plasma hormone concentrations  
by Multiplex bead array
Thirty cytokines, chemokines, growth factors, soluble recep-
tors, and acute phase proteins were measured in serum using 
different Linco-plex kits (Millipore, Billerica, MA, USA). These 
were regular sensitivity kits for Eotaxin, G-CSF, GM-CSF, GRO, 
IFNα2, IFNγ, IL-1α, IL-1β, IL-9, IL-12(p40), IP-10, MIP-1α, 
MIP-1β, TNFα, TNFβ, and VEGF; high sensitivity kits for IL-5, 
IL-8, IL-10, IL-12(p70), and IL-13; soluble receptor kits for sIL-
2Rα, sIL-4R, sIL-6R, and sVEGFRI; acute phase protein kits for 
CRP, SAP A, and SAP P; and MMP kits for MMP-2 and MMP-9. 
Metabolic hormone kits (Merck-Millipore, MI, USA) were used 
to quantify plasma concentrations of amylin (active), leptin, and 
ghrelin. T3, T4, cortisol, estradiol, and progesterone concentra-
tions were quantified using steroid/thyroid hormone kits (Merck-
Millipore). Assays were done according to the manufacturer’s 
instructions. Concentrations of the markers were measured on a 
Bio Plex platform (Bio-Plex™, Bio-Rad Laboratories, Hercules, 
CA, USA). All samples, quality controls (QCs), and inter-plate 
control were run in duplicate. Concentrations of all the analytes 
in the QCs were within the expected ranges and the inter-plate 
variation below 20%. The data generated were managed using 
Bio-Plex Manager Software, version 4.1.1.
Quantification of Plasma hormone 
concentrations by elisa
Plasma concentrations of DHEA (DRG Instruments GmbH, 
Marburg, Germany), growth hormone (Abnova, Taipei City, 
Taiwan), adiponectin (Merck-Millipore), and total amylin (Merck-
Millipore) were measured by ELISA according to the manufac-
turer’s instructions. Hormone concentrations were detected by 
a Bio-Rad Microplate reader with Microplate Manager Software, 
version 5.2 build 103 (Bio Rad Laboratories).
Data and statistical analysis
For multiplex assays, data were analyzed using the R program-
ming statistical package (The R Foundation for Statistical Com-
puting, Vienna, Austria). Missing values were imputed using 
random-forest imputation from the mice package. Data for two 
participants could not be imputed and were excluded from the 
analysis on hormone data. Fifty imputed data sets were gener-
ated for analysis. Values that were too low to be extrapolated by 
the Bio-Plex Manager Software were randomly imputed in each 
of the 50 data sets according to maximum likelihood log-normal 
distributions created for each analyte using the bbmle and 
fitdistrplus packages. Hormone concentrations were analyzed 
with a linear mixed-effects model using lmer from the lme4 
package and a glht post  hoc test from the multcomp package. 
Treatment outcome and time point were fixed effects and patient 
identification a random effect. The assumption of the mixed-
effect model was that the residuals after fitting the model were 
normally distributed. qqplots indicated outliers were present 
in estradiol, ghrelin, leptin, and DHEA with extreme outliers 
present in progesterone. To test the sensitivity of the models, 
outliers were removed using Cook’s distance metric until the 
Shapiro–Francia test, from the nortest package, did not detect 
deviation from the normal distribution at p  ≤  0.05. Results 
remained unchanged, i.e., statistical differences remained, after 
excluding the outliers. This was, however, not true for proges-
terone and we excluded the hormone from the analysis. Data 
are presented as means and SDs of the log-transformed data. To 
determine the linear relationship between different hormones 
and between hormones and cytokines, a Pearson correlation on 
quantile normalized data was used. Average Pearson correlation 
coefficients and p-values of 50 imputed data sets are reported. 
A principal component analysis (PCA) was used to evaluate the 
strengths of the relations between variables in cured and failed 
patients using the prcomp function and the bi-plots reported. 
Prediction models were developed using Elastic-Net regression 
analysis (with a parameter setting of alpha  =  0.5) from the 
glmnet package. Variables that predicted hormone or cytokine 
concentrations in more than 60% of the 50 imputed datasets 
were included in the model.
Qlucore Omics Explorer (Lund, Sweden) was used to gener-
ate heat maps of the log-transformed means of the hormones 
and Ingenuity Pathway Analysis (IPA) (Qiagen, Redwood City, 
CA, USA) used to determine the canonical pathways in which 
inflammatory markers were involved.
resUlTs
baseline characteristics
The aim of this study was to investigate immune and endocrine 
responses during the course of TB chemotherapy in patients 
with successful and unsuccessful treatment outcomes. BMI 
(kg/m2) was determined at each clinic visit and was previously 
shown to be a good predictor of poor treatment outcome (19). 
We found that the BMI increased, in both groups, during TB 
treatment, and were not different between the two groups at 
any of the three time points (Table 1). Corrections for BMI in 
subsequent analysis were therefore omitted. In addition, there 
were no differences with respect to age, sex distribution, and 
CXR score (Table 1).
FigUre 1 | Differential expression of plasma hormone concentrations before (baseline), during (week 4), and after tuberculosis treatment (month 6). Hormone 
concentrations, measured by Luminex (cortisol, T3, T4, ghrelin, leptin, and estradiol) and ELISA [dehydroepiandrosterone (DHEA), amylin (Tot), adiponectin, and 
growth hormone], were clustered according to group and time point (cured group n = 25 and failed group n = 10). Qlucore Omics explorer software was used to 
generate the heat maps around the mean hormone concentrations of the log-transformed data. Bright yellow indicates +2 (fourfold) upregulation from the mean 
(black) and bright blue indicates a −2 downregulation from the mean.
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hormone Profiles in Tb Patients changed 
during the course of Treatment
Cortisol, DHEA, and leptin concentrations in particular were 
characterized in the context of TB, by comparing the hormone 
concentrations of TB patients to those of healthy controls (4, 10). 
Limited information is available on other endogenous hormones, 
especially on how their concentrations are affected by TB treat-
ment. We thus investigated hormonal changes in individuals 
diagnosed with TB, during TB treatment. The hormone profiles 
of the two different treatment outcome groups were different 
from each other and different treatment responses were observed 
for cortisol, T4, amylin (total), and DHEA (Figure 1).
Univariate analysis showed that cortisol concentrations 
significantly decreased in cured patients from baseline (before 
TB treatment) to week 4 and remained low until the end of 
treatment, while cortisol concentrations remained unchanged 
in the failed group (Figure 2A). The concentrations of the sex 
hormone estradiol, increased during TB treatment in both 
groups (Figure  2B). Since we observed the same treatment 
response in both genders, we reported the pooled data. No 
differences were detected in growth hormone concentrations 
(Figure  2C). T3 concentrations significantly increased in the 
failed group from baseline to week 4. The increase in the same 
groups from week 4 to month 6 did not reach statistical sig-
nificance (Figure 2D). In the cured group, on the other hand, 
there was a significant increase only from baseline to week 4. TB 
treatment did not alter T4 concentrations in patients who failed 
treatment; however, in cured patients, there was a trend that T4 
concentrations decreased resulting in month 6 concentrations 
being lower than in patients who failed treatment (p = 0.050; 
Figure 2E).
Ghrelin concentrations showed an early treatment response 
with a significant decrease from baseline to week 4 in the cured 
groups and a trend toward a decrease in the failed group. Thereafter, 
in both treatment groups, ghrelin concentrations remained 
unchanged (Figure  2F). In the cured group, leptin concentra-
tions significantly increased from baseline to week 4 and again 
from week 4 to month 6 (Figure 2G). In the failed group, leptin 
concentrations significantly increased from baseline to week 4, 
but no difference was observed between week 4 and month 6. The 
increase in leptin observed during treatment is possibly due to the 
weight gain associated with TB treatment. There was a trend that 
amylin (total) concentrations increased from baseline to week 4 in 
the failed group and remained the same until the end of treatment 
(Figure 2H). In the cured group, amylin (total) concentrations 
remained unchanged from baseline to week 4 and then signifi-
cantly decreased from week 4 to month 6. At 4 weeks (p = 0.083) 
and 6 months (p = 0.050), there were trends that amylin (total) 
concentrations were lower in cured patients when compared to 
the failed patient group.
Statistical significant changes in adiponectin concentrations 
were only observed in the cured patient group (Figure  2I). 
DHEA concentrations steadily increased during treatment in the 
cured group, whereas, in the failed group, there was a significant 
increase from baseline to week 4 (Figure 2J). At week 4, there was 
a trend that the failed group had higher DHEA concentrations 
than the cured group (p = 0.056).
Further differences were observed between the two treatment 
outcome groups when the correlation matrices of the hormones 
were compared at the three time points (Figure 3). The matrices 
were used to present the Pearson correlation coefficients and 
p-values. Changes in the intensity of the colors, representing 
FigUre 2 | Changes in circulating hormone concentrations during the course of tuberculosis (TB) treatment. Plasma from TB patients (males and females) who 
were cured (n = 25) and who failed (n = 10) TB treatment were collected before (baseline) and during TB treatment (week 4 and month 6). Plasma collected was 
subjected to hormone measurement by Luminex analysis [cortisol (a), T3 (D), T4 (e), ghrelin (F), leptin (g), and estradiol (b)] and ELISA [dehydroepiandrosterone 
(DHEA) (J), amylin (Tot) (h), adiponectin (i), and growth hormone (c)]. Data were analyzed by a linear mixed-effects model of hormone concentrations by treatment 
outcome and time point as fixed effects and patient ID as random effect. Results are presented as means of the log-transformed data with SD. A p-value of < 0.05 
was regarded as significantly different. *p-value < 0.05; **p-value < 0.01; ***p-value < 0.001.
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the direction and significance of the correlations, indicated that 
there were differences in the hormone–hormone interactions 
between the two patient groups. As expected, differences were 
observed at baseline and week 4, but surprisingly there were still 
differences in the hormone interactions between the two groups 
at the end of treatment. With the major differences being the 
significant correlations in the failed group at baseline between 
ghrelin and adiponectin (r = −0.85, p = 0.00), leptin and DHEA 
(r = −0.68, p = 0.03), T3 and estradiol (r = −0.86, p = 0.00), and 
T3 and leptin (r = 0.67, p = 0.04). At month 6, the significant cor-
relations in the failed group were DHEA and cortisol (r = 0.66, 
p = 0.04), growth hormone and DHEA (r = −0.63, p = 0.05), 
T3 with leptin (r = 0.70, p = 0.02), and T4 with T3 (r = 0.72, 
p = 0.02).
During Tb Treatment, altered hormone 
concentrations correlated with immune 
Marker concentrations
In an attempt to understand the immune–endocrine interaction 
during TB treatment, we investigated whether changes observed 
in hormone concentrations correlated with concentrations of 
different immune markers measured at each of the time points. 
We aimed to determine whether the interactions between 
immune markers and hormones were different in the two treat-
ment outcome groups. Bi-plots from the PCA suggest that the 
relationships were different. For example, in the cured group, 
SAP A, IL-8, IFNγ, and CRP positively correlated with cortisol 
(Figure  4). It is possible that the increase in inflammatory 
markers during TB disease results in the increased production 
of cortisol by means of a feedback mechanism as increased 
cortisol concentrations subsequently prevent excessive immune 
responses and immunopathology. Cortisol furthermore nega-
tively correlated with DHEA, T3, sIL-4R, and leptin. In the failed 
group, interactions between IFNγ, soluble receptors, DHEA, sex 
hormones, and cortisol varied from those observed in the cured 
group (Figure 4).
Unique combinations of inflammatory markers correlated 
with each of the hormones in the cured and failed treatment 
groups and again, differences between the groups were evident 
at all three time points (Tables 2–4). During TB treatment, the 
elevated cortisol concentrations in failed patients negatively 
correlated with MMP-9 at week 4, whereas in cured patients, a 
negative correlation was found at the end of treatment with IP-10. 
FigUre 3 | Continued
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DHEA negatively correlated with inflammatory markers in the 
cured group at baseline and week 4. Interestingly, no correlations 
were found between DHEA and inflammatory markers in the 
failed group. Inflammatory markers negatively correlated with 
T3 in both the cured and failed groups at baseline. At week 4, 
inflammatory markers continued to negatively correlate with T3 
in the cured group, but no correlations were found in the failed 
group. At the end of treatment, there were no correlations with 
T3 in cured group whereas, in the failed group, TNFα positively 
correlated with T3. T4 concentrations did not correlate with 
any inflammatory markers in the cured group, but positively 
correlated with markers at week 4 and month 6 in the failed 
group. High amylin (total) concentrations in the failed group 
positively correlated with sIL-2Rα at week 4, while concentrations 
FigUre 3 | Correlations between plasma hormone concentrations of tuberculosis patients who were cured and who failed treatment at baseline, week 4, and 
month 6. Hormone concentrations were measured by Luminex analysis (cortisol, T3, T4, ghrelin, leptin, and estradiol) and ELISA [dehydroepiandrosterone (DHEA), 
amylin (Tot), adiponectin, and growth hormone] (cured: n = 25; failed: n = 10). Average Pearson correlation coefficients and p-values of 50 imputed datasets are 
presented. Correlation coefficients are expressed as percentages in the colored squares (bottom-left section) and the p-values in the white squares (top-right 
section). The colorimetric scale represents the correlation coefficient where dark blue squares indicate strong positive correlations (+1) and dark red strong negative 
correlations (−1).
7
Kleynhans et al. Immune–Endocrine Relationships during TB Treatment
Frontiers in Immunology | www.frontiersin.org June 2017 | Volume 8 | Article 690
of this hormone negatively correlated with MIP-1β at baseline in 
the cured group. These data point toward a dynamic interplay 
between the immune and endocrine system that is vastly different 
between the two treatment outcomes.
The IPA software was used to identify the biological functions 
and immunological pathways in which the group of markers 
which correlated with a particular hormone, in a particular 
response group, at a particular time point were involved, regard-
less of whether there was a positive or negative correlation. 
Canonical pathways associated with the hormones in a group 
over all time points were pooled and the unique pathways, 
which distinguished the two patient groups, reported in Table 5. 
Pathways associated with hormones in the cured group were the 
inflammasome pathway, cytokine-mediated communication 
between immune cells, VEGF ligand–receptor interactions, 
and signaling of the myeloid cell receptor, triggering receptor 
expressed on myeloid cells 1 (TREM1). Pathways associated with 
hormones in the failed group were the adhesion and diapedesis 
of agranulocytes and granulocytes, hepatic fibrosis/stellate cell 
activation, and liver X receptor (LXR) and farnesoid X receptor 
(FXR) activation (Table 5). The inflammasome pathway in the 
cured group was associated with T3 concentrations at baseline 
that correlated with IL-8 and sIL-2Rα (Table  2). The role of 
cytokines in mediating communication between immune cells 
and the TREM1 signaling pathway were both associated with 
cortisol concentrations at baseline that correlated with IL-8 and 
TNFα. The VEGF family ligand–receptor interaction pathway 
was associated with estradiol concentrations that correlated with 
VEGF at baseline. In the failed group, agranulocyte adhesion and 
diapedesis were associated with ghrelin concentrations (week 4) 
correlating with IP-10 and MMP-9 (Table 3). Granulocyte adhe-
sion and diapedesis was associated with adiponectin (week 4) 
that correlated with IFNγ, MIP-1α, sIL-4R, VEGF, and G-CSF, 
estradiol (week 4) that correlated with GRO, MIP-1β, and IL-10, 
and ghrelin (week 4) that correlated with IP-10 and MMP-9. 
Hepatic fibrosis/hepatic stellate cell activation was also associated 
with adiponectin concentrations at week 4, whereas the LXR/
retinoid-X-receptor (RXR) and FXR/RXR activation pathway 
were associated with cortisol at baseline correlating with CRP, 
SAP A, and sIL-2Rα. This indicates that markers associated with 
cortisol, T3, and estradiol at baseline drive the unique pathways, 
identified in the cured group whereas markers correlating with 
ghrelin, adiponectin, and estradiol at week 4 and cortisol at 
baseline primarily drive the pathways unique to the failed group.
hormones Predicted cytokine 
concentrations
In a further attempt to understand the interplay between the 
immune and endocrine system, we determined whether hor-
mone concentrations could predict cytokine concentrations and 
vice versa. An Elastic-Net regression was used to determine which 
markers predicted which in 50 imputed datasets and predictions 
FigUre 4 | Continued
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which occurred in at least 60% of the imputed datasets were 
reported. Not only did inflammatory markers predict hormone 
concentrations (Table  6) but some hormones also predicted 
inflammatory marker concentrations (Table 7). GRO and SAP 
A predicted ghrelin concentrations in 98% of the datasets, SAP 
P predicted ghrelin concentrations in 96%, and IL-12p40 in 92% 
of the datasets. SAP P predicted estradiol concentrations along 
with MMP-2 in 94 and 82% of the datasets, respectively. MMP-2 
furthermore predicted adiponectin concentrations in 90% of the 
datasets. G-CSF predicted T4 and leptin concentrations in 94% 
of the datasets. As expected, TNFα and IFNγ predicted cortisol 
concentrations, and this was true in 80% of the imputed datasets. 
VEGF (60%) and its receptor, sVEGFR1 (88%), predicted IFNγ 
and amylin (total) concentrations.
Hormones were also good predictors of inflammatory marker 
concentrations. Adiponectin predicted IL-12p40 concentra-
tions in all the datasets. Adiponectin, cortisol, ghrelin, and T4 
predicted IP-10 concentrations; cortisol and T4 predicted TNFα 
concentrations, cortisol, ghrelin, growth hormone, and T4 pre-
dicted CRP concentrations; adiponectin and cortisol predicted 
IFNγ concentrations; cortisol and T4 sIL-2Rα concentrations 
and adiponectin, estradiol, and T3 predicted MMP-2 concentra-
tions, all with the same frequency.
DiscUssiOn
By exploring a wide range of biological markers, including hor-
mones and inflammatory molecules, a better understanding of 
FigUre 4 | Bi-plots depicting plasma hormone and serum inflammatory marker interaction. Interactions between hormones and inflammatory markers were 
determined before tuberculosis treatment (baseline) in patients who were cured (n = 25) and those who failed (n = 10) treatment. The principal component analysis 
(PCA) was done using the prcomp function in R and the bi-plot generated using the factoextra package.
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pathogen-induced immunopathology during TB can be attained. 
In an attempt to understand these interactions during M.tb 
infection, Santucci et al. investigated the multifaceted immune– 
endocrine–metabolic alterations in patients with different sever ities 
of pulmonary TB (11). Bongiovanni et al. reported the immune–
endocrine responses during TB treatment (15). However, both 
these studies investigated a limited number of hormones and 
immunological markers.
In this report, we included a range of hormones, immunologi-
cal markers, and comprehensive correlations to investigate the 
immune–endocrine interaction. We found that the hormone pro-
file of individuals who are successfully cured after completing the 
6-month TB treatment regimen differed from those who failed 
TB treatment. We showed that estradiol, T3, leptin, and DHEA 
concentrations increased and that cortisol, T4, ghrelin, and amylin 
(total) concentrations decreased during TB treatment. Cortisol, 
T4, amylin (total), and DHEA concentrations remained lower in 
the cured patients. We furthermore showed that hormone con-
centrations correlated with different groups of immunological 
markers. We were able to identify immunological pathways for 
the groups of markers that correlated with hormones in the dif-
ferent patient groups. This study, however, has several limitations 
such as the small sample sizes and the fact that dietary intake and 
blood collection time was not standardized. Not only hormone 
but also cytokine concentrations, for instance, IL-1β are known 
to change post-prandially (20), yet this is almost never considered 
Table 7 | Hormone predictors of cytokine concentrations.
cytokines hormones predicting cytokine concentrations (%)
G-CSF T4 (0.96), cortisol (0.90), and ghrelin (0.82)
IL-12p40 Adiponectin (1.00) and ghrelin (0.98)
IP-10 Adiponectin (1.00), cortisol (1.00), ghrelin (1.00), T4 (1.00),  
and leptin (0.78)
TNFα Cortisol (1.00) and T4 (1.00)
VEGF Amylin (Tot) (0.78)
CRP Cortisol (1.00), ghrelin (1.00), growth hormone (1.00),  
and T4 (1.00)
SAP P Ghrelin (0.90)
IL-8 Cortisol (0.76)
IFNγ Adiponectin (1.00), cortisol (1.00), T4 (0.98),  
and ghrelin (0.66)
sIL-2Rα Cortisol (1.00) and T4 (1.00)
sVEGFR1 Amylin (Tot) (0.76)
MMP-2 Adiponectin (1.00), estradiol (1.00), T3 (1.00), and 
dehydroepiandrosterone (0.94)
%: percentage of 50 imputed datasets the hormone predicted the concentrations  
of the corresponding inflammatory marker.
Table 2 | Baseline correlations between hormones and inflammatory markers.
hormone inflammatory marker (Pearson correlation 
coefficient and p-value)
cured Failed
Adiponectin IP-10 (0.49; 0.01)
Amylin (Tot) MIP-1β (−0.53; 0.02)
Cortisol IL-8 (0.54; 0.02),  
TNFα (0.47; 0.03)
CRP (0.72; 0.02),  
SAP A (0.83; 0.00), 
sIL-2Rα (0.85; 0.00)
Dehydroepiandrosterone IL-5 (−0.47; 0.03),  
SAP A (−0.52; 0.01), 
CRP (−0.56; 0.00)
Estradiol VEGF (−0.49; 0.04)
T3 IL-8 (−0.51; 0.03),  
sIL-2Rα (−0.51; 0.01)
CRP (−0.72; 0.02),  
IL-5 (0.65; 0.04)
Italic text: negative correlations.
Table 3 | Week 4 correlations between hormones and inflammatory markers.
hormone inflammatory marker (Pearson correlation 
coefficient and p-value)
cured Failed
Adiponectin IFNγ (0.93; 0.00),  
MIP-1α (0.75; 0.02), 
sIL-4R (0.74; 0.01),  
VEGF (0.75; 0.02), 
G-CSF (0.65; 0.04)
Amylin (Tot) sIL-2Rα (0.67; 0.04)
Cortisol MMP-9 (−0.77; 0.01)
Dehydroepiandrosterone CRP (−0.55; 0.00),  
IP-10 (−0.47; 0.02),  
SAP A (−0.54; 0.01), 
sIL-2Rα (−0.40; 0.04)
Estradiol IFNγ (−0.47; 0.04),  
IP-10 (−0.42; 0.04),  
SAP A (−0.46; 0.02), 
TNFα (−0.49;0.04)
GRO (−0.79;0.01),  
MIP-1β (−0.66; 0.04), 
IL-10 (−0.72;0.02)
Ghrelin GRO (0.54; 0.01) IP-10 (−0.74; 0.01), 
MMP-9 (0.65; 0.04)
T3 CRP (−0.51; 0.02),  
sIL-2Rα (−0.56; 0.01)
T4 IP-10 (0.72; 0.02),  
MIP-1β (0.86; 0.00)
Italic text: negative correlations.
Table 6 | Cytokine predictors of hormone concentrations.
hormone cytokines predicting hormone concentrations (%)
Cortisol TNFα (0.80), IFNγ (0.80), IL-8 (0.70), sIL-2Rα (0.68),  
and VEGF (0.60)
Estradiol SAP P (0.94), MMP-2 (0.82), and IL-10 (0.78)
T3 sIL-4R (0.70) and MIP-1β (0.68)
T4 G-CSF (0.94)
Ghrelin GRO (0.98), SAP A (0.98), SAP P (0.96), and  
IL-12p40 (0.92)
Leptin G-CSF (0.94), GRO (0.94), IL-10 (0.90), and IL-5 (0.70)
Amylin (Tot) sVEGFR1 (0.88), IL-1β (0.78), VEGF (0.76), SAP A (0.72),  
and G-CSF (0.68)
Adiponectin MMP-2 (0.90), IP-10 (0.82), IFNγ (0.82), and  
IL-12p40 (0.72)
%: percentage of 50 imputed datasets the inflammatory marker predicted the 
concentrations of the corresponding hormone.
Table 5 | Unique canonical pathways associated with inflammatory markers 
which correlate with the hormones in patients who were cured and patients  
who were not successfully cured after tuberculosis treatment.
canonical pathways
cured Failed
Role of cytokines in mediating 
communication between immune cells
Liver X receptor/retinoid-X-receptor 
(RXR) activation
VEGF family ligand–receptor interactions Farnesoid X receptor/RXR activation
Inflammasome pathway Granulocyte adhesion and diapedesis
Triggering receptor expressed on 
myeloid cells 1 signaling
Agranulocyte adhesion and diapedesis
Hepatic fibrosis/hepatic stellate cell 
activation
Canonical pathways associated with the hormones in a group over all time points  
were pooled and the unique pathways, which distinguished the two patient groups,  
listed here.
Table 4 | Month 6 correlations between hormones and inflammatory markers.
hormone inflammatory marker (Pearson correlation 
coefficient and p-value)
cured Failed
Adiponectin IP-10 (0.83; 0.01)
Cortisol IP-10 (−0.47; 0.02)
Ghrelin MMP-2 (−0.43; 0.05), 
sIL-2Rα (−0.48; 0.02)
Growth hormone IL-5 (0.72; 0.02)
T3 TNFα (0.69; 0.03)
T4 TNFα (0.65; 0.05)
Italic text: negative correlations.
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in TB biomarker studies available in the literature and should be 
taken into account in any future studies. Despite the limitations, 
typical treatment responses were observed when looking at the 
changes in hormone concentrations during TB treatment and it 
would appear that cortisol, DHEA, T4, and amylin (total) are the 
major role players in the host response to M.tb and are potential 
marker candidates to differentiate treatment outcome.
Cortisol concentrations are higher in TB cases than in healthy 
controls at baseline and increase as disease severity increases 
(4, 11). DHEA concentrations on the other hand are lower in 
TB cases than controls and further decrease as disease severity 
increases (4). In keeping with and extending these results, we 
found that cortisol concentrations decreased during TB treat-
ment in cured patients, but remain unchanged in patients with 
a failed treatment outcome, whereas DHEA concentrations 
suddenly increased in the failed treatment outcome group from 
baseline to week 4 and gradually increase in the cured group 
during treatment. We showed that cortisol concentrations posi-
tively correlated with acute phase proteins and soluble cytokine 
receptors before TB treatment. Cytokines produced during the 
course of the immune response induce alterations in the con-
centrations of hormones produced by the HPA, HPT, and HPG 
axis (21). The positive correlation observed between cortisol 
and inflammatory markers at baseline forms part of a feedback 
mechanism to limit the inflammatory response associated with 
active disease.
T3 and its precursor, T4, are primarily involved in metabolism 
and T3 promotes the production of pro-inflammatory markers 
(22). T3 and T4 also promote the catabolic state in TB patients 
(4). In some studies, T3 and T4 concentrations were found to be 
higher in TB patients (4, 23), while in others they were lower in TB 
patients and increased during TB treatment (24, 25). Extremely 
low T3 concentrations have been further associated with mortal-
ity in TB patients (25). We found that T3 concentrations increased 
during TB and that T4 concentrations remained unchanged in the 
failed group. T4 concentrations were lower in the cured group, 
compared to the failed group, at month 6.
Leptin concentrations are lower in TB patients (11) and 
low leptin concentrations and increased IL-6 concentrations 
are associated with wasting and weight loss in TB patients 
(26). Santucci et al. found a positive correlation between leptin 
concentrations and BMI (11), while another study found no 
correlation between these two parameters (27). Animal experi-
ments suggest that leptin contributes to protection against M.tb 
by inducing Th1 cytokine responses (28). Such a role has not yet 
been conclusively shown in humans (11, 26, 29, 30). Some have 
suggested that leptin does not form part of the pro-inflammatory 
response (30) and in agreement with this, leptin did not cor-
relate with any of the inflammatory markers investigated in this 
study. Ghrelin, which is produced by the stomach and acts as 
an orexigenic factor (31), is present at higher concentrations in 
TB patients and the increase in ghrelin concentrations could 
act as a compensatory mechanism to weight loss (27). Ghrelin 
can furthermore downregulate pro-inflammatory cytokine 
responses (32, 33). Our results suggest that ghrelin is involved 
in cytokine responses during TB treatment as some markers 
correlated with ghrelin.
Amylin, which is secreted in conjunction with insulin to main-
tain blood glucose concentrations, has been found to be higher in 
obese individuals than in their normal-weight counterparts and 
was positively associated with BMI and inflammatory markers 
like CRP and IL-6 (34). Our study, the first to measure amylin 
in TB patients, showed that amylin concentrations were higher 
in the failed group, during treatment, than in the cured group. 
Amylin concentrations were not only associated with inflamma-
tory markers but have been found to induce the production of 
acute phase proteins (35) and to activate the NLRP3 inflamma-
some (36). We found amylin to be positively and negatively cor-
related with inflammatory markers in the failed and cured group, 
respectively, indicating that this hormone plays an important role 
in immunity to TB.
Distinct biological pathways were associated with the two 
treatment outcome groups. Cytokines in the cured group were 
associated with components of the innate immune system like the 
inflammasome pathway and TREM1 receptor. Gain-of-function 
gene variants in components of the inflammasome like the NLRP3 
gene and CARD8 gene enhance inflammasome activity and limit 
M.tb growth in human macrophages (37). In addition, the adap-
tor protein PYCARD (ASC) plays an important role in granuloma 
formation (38), while M.tb prevents inflammasome activation 
and IL-1β production to survive in macrophages (39). There 
was furthermore an association with VEGF signaling in cured 
patients. It has been shown that the expression of genes involved 
in angiogenesis is upregulated and the expression of VEGF-A, 
a key regulator of angiogenesis, has been found to be higher in 
M.tb-infected macrophages which promoted the formation of 
blood vessels (40). Inhibition of VEGF reduces dissemination of 
M.tb, and it is believed that mycobacteria exploit macrophages to 
disseminate by inducing the formation of blood vessels. VEGF 
has also been observed to be higher in patients with pulmonary 
TB, and it has been classified as a biomarker to distinguish latent 
infection and active disease (40, 41). It is therefore possible that 
the favorable treatment outcome in cured patients is due to early 
inflammasome involvement and the inhibition of the angiogen-
esis pathway.
Liver X receptors activation, associated with failed group, is 
known to regulate lipid metabolism and antimicrobial responses. 
DNA sequencing of the LXRA and LXRB receptors revealed 
common variants of which some were potential risk haplotypes 
while others were protective for TB (42). LXRs therefore play in 
important role in the genetic susceptibility to TB and possibly 
treatment outcome.
Changes observed in the cured group, such as the decrease 
in cortisol level and the gradual increase in DHEA, together 
with the markers associated with these hormones in this 
group, were possibly indicative of the restoration of the 
immunological responses during TB treatment and translated 
to the improvement of the clinical conditions of the patients. 
These results, furthermore, suggested that the inflammatory 
markers and the hormones were differentially regulating each 
other.
This study showed that hormone concentrations changed as a 
result of active TB and continued to change during TB treatment 
and that hormone profiles of individuals who were successfully 
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